HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

LRRK2-IN1

inhibits leucine-rich repeat kinase 2; structure in first source

Also Known As:

LRRK2-IN-1

Networked: 4 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - LRRK2-IN1: 4
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzazepines: 5
      - Benzodiazepines: 8452
        Benzodiazepinones
        LRRK2-IN1: 4

Experts

1.	Li, Weichao: 1 article (01/2018)
2.	Tan, Dan: 1 article (01/2018)
3.	Tang, Guanghui: 1 article (01/2018)
4.	Wong, Nai-Kei: 1 article (01/2018)
5.	Xiao, Youli: 1 article (01/2018)
6.	Yang, Mengquan: 1 article (01/2018)
7.	Zhou, Yiqing: 1 article (01/2018)
8.	Courade, Jean-Phillippe: 1 article (01/2015)
9.	Garcia-Ladona, Javier: 1 article (01/2015)
10.	Gerets, Helga: 1 article (01/2015)

Related Diseases

1.	Parkinson Disease (Parkinson's Disease) 01/01/2015 - "Alternative to LRRK2-IN-1 for Pharmacological Studies of Parkinson's Disease." 04/01/2011 - "LRRK2-IN-1 will serve as a versatile tool to pharmacologically interrogate LRRK2 biology and study its role in Parkinson's disease." 01/01/2018 - "Chemoproteomics Reveals the Antiproliferative Potential of Parkinson's Disease Kinase Inhibitor LRRK2-IN-1 by Targeting PCNA Protein."
2.	Neoplasms (Cancer) 05/06/2014 - "Here we report that LRRK2-IN-1 demonstrates potent anti-cancer activity including inhibition of cancer cell proliferation, migration, and invasion as well as induction of apoptosis and cell cycle arrest. " 01/01/2018 - "Our current findings suggest the potential of LRRK2-IN-1 as a novel pharmacological molecule for scrutinizing cell physiology and furnish a logical foundation for the future development of therapeutic reagents for cancer." 01/01/2018 - "LRRK2-IN-1 was found to induce cell cycle arrest as well as cancer cell death by specifically binding to human proliferating cell nuclear antigen (PCNA) in cancer cells. " 01/01/2018 - "LRRK2-IN-1, one of the first selective inhibitors of leucine-rich repeat kinase 2 (LRRK2), was serendipitously found to exhibit potent antiproliferative activity in several types of human cancer cells. "
3.	Pancreatic Neoplasms (Pancreatic Cancer) 05/06/2014 - "Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1."

Related Drugs and Biologics

1.	Phosphotransferases (Kinase)
2.	Proliferating Cell Nuclear Antigen (PCNA)
3.	Proteins (Proteins, Gene)
4.	Leucine (L-Leucine)
5.	Indicators and Reagents (Reagents)
6.	Doublecortin-Like Kinases